RARE Jan 2025 70.000 call
| Previous close | 0.7700 |
| Open | 0.7700 |
| Bid | 0.0000 |
| Ask | 1.8500 |
| Strike | 70.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.7700 - 0.7700 |
| Contract range | N/A |
| Volume | |
| Open interest | 503 |
GlobeNewswireUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 45,525 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Emplo
- GlobeNewswire
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced the pricing of its underwritten public offering of 7,435,898 shares of its common stock at a price to the public of $39.00 per share. In addition, in lieu of issuing common stock to certain investors, the company is offering pre-funded warran
ZacksUltragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.
